Interaction of nine forms of human hepatic cytochromes P450 (CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4) with two N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-based doxorubicin (DOX) conjugates designed for passive tumor targeting was studied using pooled human microsomes. The compounds used in this study were two high-molecular-weight HPMA copolymers bearing doxorubicin attached to the polymeric carrier by 1) hydrazone bond enabling intracellular pH-controlled drug release or 2) amide bond through enzymatically cleavable tetrapeptide GlyPheLeuGly spacer. Both polymeric conjugates differing in mechanism of their antitumor activity and the free doxorubicin as the control were tested for potential inhibition activity. Among nine cytochrome P450 forms studied, no HPMA copolymer with bound DOX caused an inhibition of potential clinical significance. The extent of inhibition of enzymatic activities of the cytochrome P450 forms studied was negligible with the exception of CYP2B6 and was apparently caused by DOX as no inhibition was observed with polymers alone, and the extent of inhibition by the complex corresponded to this of the free DOX at the same concentration. In conclusion, the polymers and their conjugates with DOX seem to be relatively safe, at least in this respect, i.e., of inhibition of the liver microsomal drug-metabolizing enzymes.
Introduction
Foreign substances entering the body are, in most cases, biotransformed to more polar compounds to facilitate their excretion from the organism (Parkinson and Ogilvie, 2008) . Among enzymes taking part in these reactions, the liver microsomal cytochromes P450 (P450s) are the most important ones as they are responsible for more than one-half of known pathways of drug metabolism in the liver and other organs (Anzenbacher and Anzenbacherova, 2001 ). P450s form a superfamily of enzymes localized in the liver, lung, gastrointestinal tract, brain, heart, and in other tissues. Among liver microsomal P450s, nine forms (CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4) are active in metabolism of more than 90% reactions catalyzed by these enzymes. The importance of studies aimed at investigating their interactions with drugs and newly designed active compounds is given by the fact that many compounds may be converted by these enzymes either to less active or, on the contrary, to more active molecules and that there is a possibility of a competition of a drug for these proteins causing drug interactions, leading to increasing, even toxic, levels of the respective drugs (Bachmann et al., 2004) .
Two types of N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-doxorubicin (DOX) have been developed exhibiting significant anticancer activity (as demonstrated in mice bearing various tumor models) (Duncan et al., 1989; Kovar et al., 2002; Ulbrich et al., 2003) . In the conjugates, DOX was attached to the HPMA copolymer carrier either via an oligopeptide GlyPheLeuGly spacer susceptible to enzymatic hydrolysis with lysosomal enzymes in lysosomes of target cells (amide conjugate; Fig. 1 ) (Kopecek et al., 2000) or via a hydrazone bond and aminohexanoic acid residue in a spacer susceptible to pH-dependent hydrolysis (hydrazone conjugate; Fig. 2 ) (Etrych et al., 2001 . Both conjugates were found to be fairly stable in blood circulation and releasing DOX in lysosomes (amide conjugate) or in a mild acidic environment of tumor tissue or in endosomes of cancer cells (hydrazone conjugate). Both polymer conjugates exhibited significantly prolonged blood clearance and enhanced accumulation in solid tumors in mice (passive targeting) because of the EPR effect (Etrych et al., 2001 (Etrych et al., , 2008a Lammers et al., 2007) . Moreover, two amide conjugates, nontargeted and galactose-targeted HPMA copolymer-DOX conjugates (Vasey et al., 1999; Seymour et al., 2009) , showed in Phases I and II of clinical studies limited side effects and improved anticancer activity suggesting the polymer-doxorubicin conjugates for further development as promising drugs for treatment of cancer in humans (breast, lung, colorectal) .
It was shown that detailed structure of the spacer and form of drug attachment in the HPMA copolymer-DOX conjugates significantly influences the mechanism of drug release, interaction of the conjugates with cells, the intracellular distribution of the conjugates, their antiproliferative effect, and cell death signals they trigger (Hovorka et al., 2006; Kovar et al., 2007) .
In this study, additional results of detailed analysis of properties of both types of polymer drugs are shown, namely results of evaluation of interaction of the conjugates with the liver microsomal cytochromes P450 bringing information on susceptibility of the conjugates to metabolic elimination processes in liver. Such information is important for understanding of the mechanism of action of the polymer-DOX drugs and proper design and further development of the conjugates. In this study, behavior of two polymer conjugates with DOX (amide and hydrazone) and respective polymer carriers used as controls (for conjugates structures, see Figs. 1 and 2) was compared with properties of the free drug [doxorubicin hydrochloride (DOX⅐HCl)].
Materials and Methods
Chemicals. 1-Aminopropan-2-ol (AP); methacryloyl chloride, 2,2Ј-azobis(isobutyronitrile) (AIBN), methyl 6-aminohexanoate hydrochloride, N,NЈ-dicyclohexylcarbodiimide, N-ethyldiisopropylamine, dimethyl sulfoxide (DMSO), hydrazine hydrate, amino acids glycine, phenylalanine, and leucine, and solvents (analytical grade) were purchased from Fluka (Buchs, Switzerland). Solvents were dried and purified by conventional procedures and distilled before use. DOX⅐HCl was purchased from Meiji Seika (Tokyo, Japan).
For determination of P450 activities, chlorzoxazone, 6-hydroxychlorzoxazone, diclofenac, 4-hydroxydiclofenac, bufuralol, 6-hydroxybufuralol, and 6␤-hydroxytestosterone were supplied by Cerilliant Corporation (Round Rock, TX). P450-Glo substrates luciferin ME (luciferin-6Ј methyl ether), luciferin H (6Ј-deoxyluciferin), and luciferin BE (luciferin-6Ј benzyl ether) for evaluation of CYP2C8, CYP2C9, and CYP3A4 activities by luminescence spectrometry were products of Promega (Madison, WI) obtained through East Port (Prague, Czech Republic). 7-Ethoxy-4-(trifluoromethyl)coumarin was supplied by Fluka. Cryopreserved human liver microsomes (pooled) were purchased from Advancell (Barcelona, Spain). Microsomes were obtained under approval of the local ethic committee and in accordance with the ethic regulations of the country of origin (Spain). They were from five males and five females with a protein content of 38.4 mg/ml; the CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2E1, and CYP3A4 enzyme activities are accessible at the Advancell web site (www.advancell.net; batch reference 102091201). All other chemicals were supplied by Sigma-Aldrich (Prague, Czech Republic).
Synthesis of Monomers, Polymer Precursors, and Polymer Conjugates. N-(2-Hydroxypropyl)methacrylamide, methacryloylglycylphenylalanylleucylglycin, and its 4-nitrophenyl ester (MA-GFLG-ONp) were synthesized as described by Ulbrich et al. (2000) . 6-Methacrylamidohexanohydrazide (Ma- ah-NHNH 2 ) was prepared by the reaction of methyl 6-aminohexanoate hydrochloride with methacryloyl chloride followed by hydrazinolysis of the methylester as described by Etrych et al. (2008b) . Purity and composition of all monomers was tested by NMR, high-performance liquid chromatography using RP C18 column, melting point, and elemental analysis. Monomers were chromatographically pure (Ͼ98%), and their characteristics corresponded with those given in respective papers (Ulbrich et al., 2000; Etrych et al., 2008b) .
Polymer precursor, a copolymer of HPMA with MA-GFLG-ONp, was prepared by radical precipitation polymerization in acetone using AIBN as initiator. Polymer precursor contained 4.5 mol% of 4-nitrophenoxy (ONp) groups [determined by UV spectrophotometry ( ϭ 9500 liter mol Ϫ1 cm Ϫ1 , ϭ 274 nm, DMSO]. Polymer amide conjugate with DOX [poly(HPMA-co-MA-GFLG-DOX)] was prepared by aminolysis of the polymer precursor with DOX⅐HCl in DMSO using N-ethyldiisopropylamine as a base. For detailed synthesis and characterization, see Ulbrich et al. (2000) . The molecular weight of the polymer conjugate was 66,000 g mol Ϫ1 , polydispesity was 1.89, and content of DOX was 7.9 wt.% (determined spectrophotometrically in distilled water, ϭ 11 500 liter mol Ϫ1 cm Ϫ1 at ϭ 488 nm). The content of free DOX in the conjugate was Ͻ0.02 wt.% (related to total DOX content). The control sample, polymer carrier poly(HPMA-co-MA-GFLG-AP), was prepared by aminolysis of the polymer precursor with 10-fold excess of AP in DMSO; the product was isolated and purified by precipitation and reprecipitation into the mixture aceton/diethyl ether (3:1). The content of oligopeptide groups terminating in AP was 4.5 mol% (estimated by amino acid analysis).
The copolymer of HPMA with Ma-ah-NHNH 2 (poly(HPMA-co-MA-ah-NHNH 2 ) containing free hydrazide groups was prepared by radical solution copolymerization of respective monomers in methanol using AIBN as described previously (Etrych et al., 2008b) . The molecular weight of the copolymer was 27,000 g mol
Ϫ1
, polydispersity was 1.8, and content of hydrazide groups determined by the trinitrobenzene sulfonic acid method was 5.8 mol%. The hydrazone conjugate poly(HPMA-co-MA-ah-NHNϭDOX was prepared by the reaction of polymer precursor poly(HPMA-co-MA-ah-NHNH 2 with DOX⅐HCl in methanol containing a catalytic amount of acetic acid. The reaction was carried out in the dark as described previously (Etrych et al., 2001 ). The molecular weight of the copolymer was 32,000 g mol Ϫ1 , polydispersity was 1.8, and content of DOX was 9.8 wt.% (UV-visible spectrophotometry). The content of free DOX was Ͻ0.1 wt.% (related to total DOX content). Molecular weights of all copolymers were determined with the FPLC Pharmacia system equipped with differential refractometer Optilab T-rEX, UV, and multiangle light-scattering DAWN DSP-F Wyatt Technology Corporation (Santa Barbara, CA) detectors using 0.3 M acetate buffer (pH 6.5) and a Superose 6 column.
Determination of P450 Activities. Activities of individual P450 forms were measured according to published protocols. All the tested microsomal P450 activities and corresponding methods of specific product detection are listed in Table 1. A TECAN Infinite M200 microplate reader (Tecan Austria, Vienna, Austria) was used for detection of the fluorescence-and luminescence-based assays. High-performance liquid chromatography analyses were performed using the Prominence system (Shimadzu, Kyoto, Japan).
Fresh stock solutions of hydrazone and amide conjugate, polymer precursors, and DOX⅐HCl in ultrapure water were made before each P450 activity assay. In hydrazone and amide conjugate stock solution, the concentration of DOX was 40 g/ml (74 M). Polymer precursors were dissolved to a concentration that is equivalent to the respective polymer conjugate solutions; the free DOX⅐HCl stock solution concentration was 400 g/ml (0.74 mM). The stock solutions described here were added to reaction mixtures to obtain the desired final concentration of the tested drug; no drug and only ultrapure water was added to the control sample.
Final incubation mixture volumes were as follows: CYP1A2, CYP2A6, and CYP2B6, 100 l; CYP2C8, 100 l; CYP2C9, 100 and 50 l for diclofenac or 6Ј-deoxyluciferin as substrates; CYP2C19 and CYP2D6, 200 l; CYP2E1, 500 l; CYP3A4 activities, 500 l for testosterone and 50 l for luciferin derivative as substrate. The reaction mixtures of all P450 activities tested were buffered by 75 mM K-phosphate buffer (pH 7.4).
For each enzyme assay, a preliminary experiment was done to determine the K M and V max for a given enzyme reaction and to obtain the values of substrate concentrations suitable for the inhibition experiments (as a rule, substrate concentration was chosen in the range corresponding to the value of the K M ). Inhibition experiments were routinely performed with up to seven concentrations of the tested drug. A control experiment with known reference inhibitors was implemented in cases in which a significant degree of inhibition was presumed, namely with sulfaphenazole (CYP2C9) (Brown et al., 2006) , methoxsalen (CYP2A6) (Kharasch et al., 2000) , diethyldithiocarbamate (CYP2E1) (Bourrie et al., 1996; Guengerich, 2006) , and 3-isopropenyl-3-methyldiamantane (CYP2B6) (Stiborova et al., 2002) .
Inhibition of individual P450 activities by HPMA copolymer-DOX conjugates or free DOX was, in all cases, evaluated by plotting the respective remaining activity against the inhibitor concentration; as a rule, the results were expressed as means of two to five independent determinations with the difference between duplicates being lower than 15%. When an inhibition was pronounced, the K i values were determined from Dixon plots with three substrate concentrations used (corresponding to 0.5 K M , K M , and 2 K M ). To get information on the mechanism of inhibition, both Dixon and Lineweaver-Burk plots were used (Segel, 1993) . To analyze the course of the enzyme kinetics, parameters of enzyme kinetics (K M , V max ) and the intercepts of the respective plots were obtained using SigmaPlot 8.0.2 (SPSS Inc., Chicago, IL) and GraphPad Prism 5 (GraphPad Software, San Diego, CA) scientific graphing software.
Results
Possible interactions of the conjugates, poly(HPMA-co-MA-GFLG-DOX) and poly(HPMA-co-MA-ah-NHNϭDOX), and their polymer precursors and free DOX⅐HCl with activities of nine forms of P450 enzymes present in human liver microsomes (CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4) were studied. The results show that within the DOX concentration range up to 18 M [corresponding approximately to levels attainable in human plasma (Vaclavikova et al., 2008) ], none of the studied P450 activity was affected except for CYP2D6 (activity decrease between 10 and 25%).
For comparison, the free DOX⅐HCl and the polymeric precursors without bound DOX were also tested with respect to their ability to influence P450 activities. Polymeric precursors did not affect any of the P450 forms studied (at the same concentration range as HPMA copolymer-DOX conjugates). The results of inhibition studies with the free DOX⅐HCl were nearly identical as with DOX bound through both types of conjugates (hydrazone and PK1), which means that only CYP2B6 activity was remarkably affected (decrease to 60% of control) and the CYP1A2, 2A6, 2C8, and 2E1 forms were affected only slightly (activity decrease between 10 and 25%).
Inhibition of CYP2B6 activity by free DOX as well as by DOX bound in hydrazone or amide conjugate (at concentrations 0 to 18 M) is shown in Fig. 3 . The results clearly show that independently on the mode of binding, DOX acts as a moderate inhibitor of CYP2B6 activity. In Fig. 3 , inhibition data for free DOX at higher levels are also presented.
To obtain information on whether free DOX⅐HCl at higher concentrations is able to inhibit P450 enzymes in a more pronounced extent, the free DOX⅐HCl was tested also for 10 times higher concentration equal to 184 M. Here, the concentrated DOX⅐HCl affected markedly almost all studied P450 activities. The most prominent effect was observed at the CYP2B6 form, which was nearly completely inhibited with DOX at 184 M (Fig. 4) . Activities of the CYP2C8, CYP2C19, and CYP3A4 forms (all of them were inhibited down to 30% of control) and the CYP1A2 form (decrease to 40% of control) were affected significantly as well (Fig. 4) . Apparent inhibition was observed also at CYP2A6, CYP2E1, and CYP2D6 activities; however, the remaining activity was still higher than 60% of control even at DOX concentration of 184 M. The last activity tested, the CYP2C9 one, was not affected at all even at the DOX⅐HCl concentration reaching 184 M.
The enzyme activities of P450 forms, which exhibited the decrease by DOX exceeding 50% of control (i.e., CYP1A2, 2B6, 2C8, 2C19, and 3A4) (Fig. 4) , were analyzed using Dixon and Lineweaver-Burk plots (Segel, 1993) to evaluate the possible mechanisms of enzyme inhibition (Burlingham and Widlanski, 2003) . In the case of CYP1A2, CYP2C8, CYP2C19, and CYP3A4, the courses of the Dixon and Lineweaver-Burk plots indicate a noncompetitive mechanism of inhibition, which means an inhibition of product formation by the presence of an inhibitor (the inhibitor is bound in a site close to the substrate binding site; however, the inhibition is not conditioned by a conformational change of the active site because of the previous binding of a substrate). Data for CYP2C8 and CYP2B6 are shown (Figs. 5, A and B, and 6, A and B) , and the courses of the Dixon and Lineweaver-Burk plots are similar for CYP3A4. The K i value is at approximately 75 M for CYP1A2 activity, at approximately 30 M for CYP2C19 activity, and at approximately 55 M for the CYP3A4 activity. A similar case of noncompetitive inhibition was also observed for inhibition of the CYP2C8 activity. The course of the Dixon 
DOXORUBICIN CONJUGATES INTERACT WITH HUMAN CYTOCHROMES P450
at ASPET Journals on November 6, 2017 dmd.aspetjournals.org plot corresponds well to noncompetitive inhibition for lower concentrations of DOX (up to approximately 110 M) (Fig. 5A) , with the K i matching 90 M.
In the case of inhibition of CYP2B6 activity (which was the most affected one; see Figs. 3 and 4), the Dixon and the Lineweaver-Burk plots indicated a strongly bound inhibitor. The Dixon plot shows an upright curvature typical for a strongly bound inhibitor (Fig. 6A) , and the Lineweaver-Burk plot (Fig. 6B) is known to exhibit, in this case (of strongly bound inhibitor), the same course as for noncompetitive with an intercept at the x-axis indicating the K i value of approximately 90 M.
Discussion
The results obtained in this study with two HPMA copolymer-DOX conjugates differing in mechanism of DOX release and mechanism of cytotoxic activity point to identical character of their interactions with the main liver microsomal systems of drug biotransformation, namely with the P450 enzymes. We were surprised to find that both polymer 
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at ASPET Journals on November 6, 2017 dmd.aspetjournals.org conjugates, the hydrazone conjugate and the amide conjugate, exhibit only a minor effect on activities of selected microsomal P450s being thus safe drugs in the light of drug interactions based on this effect. In fact, within common therapeutic concentration levels of DOX, i.e., below 18 M, hydrazone and amide conjugates inhibited markedly only one activity, CYP2B6. CYP1A2, 2A6, 2C8, and 2E1 activity, as well as the activity of the most important P450 form, CYP3A4 (metabolizing majority of drugs converted by P450 enzymes), was inhibited at the therapeutic concentration only slightly, and the decrease was not greater than 20% at the highest concentration of the drug conjugate. Polymer precursors of both conjugates did not inhibit P450 activities at all.
In other words, the inhibition experiments with both types of HPMA polymers either with DOX conjugated or without bound drug yielded rather weak and, most probably, clinically not relevant inhibition of activities of individual P450 enzymes. As described earlier, the CYP2B6 was the only exception. The extent of inhibition at concentrations of DOX corresponding to levels in plasma was more than 40% and corresponded to the extent of inhibition of P450 activities with free DOX⅐HCl at the same concentration.
The comparative experiments performed with free DOX⅐HCl revealed that the free drug affects the same P450 activities, and in the same extent as conjugates with bound drug. Therefore, DOX is responsible for inhibition properties of the HPMA copolymer conjugates, and attachment of the drug to a macromolecular carrier does not significantly influence its inhibitory properties, although conjugation of DOX with the same polymer carriers results in a dramatic decrease in systemic toxicity and significant improvement in anticancer activity depending on the detailed structure of the polymer carrier system. At higher DOX concentrations, the In Vitro inhibition experiments were performed. The mechanism of P450 inhibition was according to the noncompetitive kinetic analysis, and for the CYP2B6 form, the results were interpreted in favor of a strongly bound inhibitor (DOX). In other words, the results indicated a possible influence of DOX⅐HCl on processes not directly related to substrate binding, however, hampering the enzyme reaction. Here, the possibility of influencing the electron transfer by interaction with residues at the surface of the enzyme or by blockade of the substrate/product access/egress channels may be speculated (Otyepka et al., 2007) . The inhibition of CYP2B6 activity was markedly less specific (with a K i value of 90 M) compared with the specific inhibitor used, 3-isopropenyl-3-methyldiamantane, which exhibits a K i value of 2 M (Stiborova et al., 2002) .
This mode interaction (not affecting directly the substrate binding site of P450 enzymes) may explain both 1) relatively low specificity of DOX⅐HCl or DOX conjugate-P450 interactions and 2) the fact that both types of HPMA conjugates (although of different properties and structurally diverse) behave, in this respect, in a similar way. The fact that only one P450 enzyme (CYP2B6) exhibited a relatively specific inhibition by DOX⅐HCl is in line with an earlier finding that the rat CYP2B1 form also was found to be inhibited by this drug. The explanation of the inhibition was based on an impairment of the electron transfer, which may support the reasoning of a possible mechanism of P450 inhibition by influencing the residues at the surface of the P450 macromolecule in both enzymes of the CYP2B family.
Together, the DOX conjugates may be expected to be relatively safe anticancer therapeutic agents, at least most probably not influencing the enzyme activities of drug liver P450 enzymes. 
